The Significance of HIV ‘Blips’ in Resource-Limited Settings: Is It the Same? Analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD)
Introduction Magnitude and frequency of HIV viral load blips in resource-limited settings, has not previously been assessed. This study was undertaken in a cohort from a high income country (Australia) known as AHOD (Australian HIV Observational Database) and another cohort from a mixture of Asian countries of varying national income per capita, TAHOD (TREAT Asia HIV Observational Database). Methods Blips were defined as detectable VL (≥ 50 copies/mL) preceded and followed by undetectable VL (<50 copies/mL). Virological failure (VF) was defined as two consecutive VL ≥50 copies/ml. Cox proportional hazard models of time to first VF after entry, were developed. Results 5040 patients (AHOD n = 2597 and TAHOD n = 2521) were included; 910 (18%) of patients experienced blips. 744 (21%) and 166 (11%) of high- and middle/low-income participants, respectively, experienced blips ever. 711 (14%) experienced blips prior to virological failure. 559 (16%) and 152 (10%) of high- and middle/low-income participants, respectively, experienced blips prior to virological failure. VL testing occurred at a median frequency of 175 and 91 days in middle/low- and high-income sites, respectively. Longer time to VF occurred in middle/low income sites, compared with high-income sites (adjusted hazards ratio (AHR) 0.41; p<0.001), adjusted for year of first cART, Hepatitis C co-infection, cART regimen, and prior blips. Prior blips were not a significant predictor of VF in univariate analysis (AHR 0.97, p = 0.82). Differing magnitudes of blips were not significant in univariate analyses as predictors of virological failure (p = 0.360 for blip 50–≤1000, p = 0.309 for blip 50–≤400 and p = 0.300 for blip 50–≤200). 209 of 866 (24%) patients were switched to an alternate regimen in the setting of a blip. Conclusion Despite a lower proportion of blips occurring in low/middle-income settings, no significant difference was found between settings. Nonetheless, a substantial number of participants were switched to alternative regimens in the setting of blips.
References
[1]
Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, et al. (2002) Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS16: 1967–9. doi: 10.1097/00002030-200209270-00017
[2]
Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, et al. (2001) Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA 2001 286: 171–9. doi: 10.1001/jama.286.2.171
[3]
Sklar PA, Ward DJ, Baker RK, Wood KC, Gafoor Z, et al. (2002) Prevalence and clinical correlates of HIV viremia (‘blips’) in patients with previous suppression below the limits of quantification. AIDS 2002 16: 2035–41. doi: 10.1097/00002030-200210180-00008
[4]
Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, et al. (2005) Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 293: 817–29. doi: 10.1001/jama.293.7.817
[5]
Lee PK, Kieffer TL, Siliciano RF, Nettles RE (2006) HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother 57: 803–5. doi: 10.1093/jac/dkl092
[6]
Mira JA, Macías J, Nogales C, Fernández-Rivera J, García-García JA, et al. (2002) Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther 7: 251–6.
[7]
Cohen Stuart JW, Wensing AM, Kovacs C, Righart M, de Jong D, et al. (2001) Transient relapses (“blips”) of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr 28: 105–13. doi: 10.1097/00042560-200110010-00001
[8]
Easterbrook PJ, Ives N, Waters A, Mullen J, O’Shea S, et al. (2002) The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to <400 copies/ml. AIDS 16: 1521–7. doi: 10.1097/00002030-200207260-00009
[9]
Di Mascio M, Markowitz M, Louie M, Hogan C, Hurley A, et al. (2003) Viral blip dynamics during highly active antiretroviral therapy. J Virol 77: 12165–72. doi: 10.1128/jvi.77.22.12165-12172.2003
[10]
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih.gov/contentfiles？/lvguidelines/adultandadolescentgl/pdf. accessed last 16/12/2013.
[11]
García-Gascó P, Maida I, Blanco F, Barreiro P, Martín-Carbonero L, et al. (2008) Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother 61: 699–704. doi: 10.1093/jac/dkm516
[12]
Martinez V, Marcelin AG, Morini JP, Deleuze J, Krivine A, et al. (2005) HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 19: 1065–9. doi: 10.1097/01.aids.0000174453.55627.de
[13]
Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ (2007) Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis 196: 1773–8. doi: 10.1086/523704
[14]
Raboud JM, Rae S, Woods R, Harris M, Montaner JS (2002) Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS 16: 1627–32. doi: 10.1097/00002030-200208160-00008
[15]
Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, et al. (2005) Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 41: 1326–32. doi: 10.1086/496985
[16]
Grennan JT, Loutfy MR, Su D, Harrigan PR, Cooper C, et al. (2012) Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis 205: 1230–8. doi: 10.1093/infdis/jis104
[17]
Moore AL, Youle M, Lipman M, Cozzi-Lepri A, Lampe F, et al. (2002) Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS 16: 615–8. doi: 10.1097/00002030-200203080-00013
[18]
Masquelier B, Pereira E, Peytavin G, Descamps D, Reynes J, et al. (2005) Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J Clin Virol 33: 75–8. doi: 10.1016/j.jcv.2004.11.012
[19]
Shen L, Siliciano RF (2008) Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 122: 22–8. doi: 10.1016/j.jaci.2008.05.033
[20]
Jones LE, Perelson AS (2005) Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART. Bull Math Biol 67: 1227–51. doi: 10.1016/j.bulm.2005.01.006
[21]
Stosor V, Palella FJ Jr, Berzins B, Till M, Leake A, et al. (2005) Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin Infect Dis 41: 1671–4. doi: 10.1086/498025
[22]
Verhofstede C, Van Wanzeele F, Reynaerts J, Mangelschots M, Plum J, et al. (2010) Viral load assay sensitivity and low level viremia in HAART treated HIV patients. J Clin Virol 47: 335–9. doi: 10.1016/j.jcv.2010.01.008
[23]
Gueudin M, Plantier JC, Lemée V, Schmitt MP, Chartier L, et al. (2007) Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr 44: 500–5. doi: 10.1097/qai.0b013e31803260df
[24]
Ruelle J, Debaisieux L, Vancutsem E, De Bel A, Delforge ML, et al. (2012) HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability. BMC Infect Dis 12: 100. doi: 10.1186/1471-2334-12-100
